Nextbiotix Receives €7 Million for Development of Bacteria-based IBD Therapy

Nextbiotix Receives €7 Million for Development of Bacteria-based IBD Therapy
Nextbiotix has secured €7 million ($8.2 million) in funding to develop NBX1650, the company’s lead bacterial candidate for the treatment of inflammatory bowel disease (IBD). This first round of funding was led by Auriga Partners, with Sofimac Innovation, Cap Innov’Est, INRA, and Biocodex also contributing. “I am particularly proud to see Nextbiotix coming out of the ground of the longstanding relationship we have established with Auriga Partners over the last year and a half. The support of our incubators Paris Biotech Santé and Wilco was also pivotal in this success. Together we have managed to assemble a very robust and complementary team of investors bringing a wide range of expertise to the table. We are delighted to have raised a first round of financing significant enough to support our efforts in bringing a revolutionary new class of medicines, called Live Biotherapeutics, to patients,” Benjamin Hadida, CEO of Nextbiotix, said in a press release. France-based Nextbiotix was co-founded by a team of researchers who led the discovery of Faecalibacterium prausnitzii, a naturally occurring gut bacteria that actively reduces inflammation and regulates immune activity in the digestive tract. Researchers Harry Sokol, MD, PhD, a professor of gastro-enterology at
Subscribe or to access all post and page content.